1312756-35-6

Basic information

• Product Name: (S)-3-methylpyrrolidin-3-ol
• Synonyms: (3S)-3-methylpyrrolidin-3-ol;(S)-3-methylpyrrolidin-3-ol
• CAS NO: 1312756-35-6
• Molecular Formula: C5H11NO
• Molecular Weight: 101.14694
• Mol File: 1312756-35-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 169.9±15.0 °C(Predicted)
• Appearance: /
• Density: 1.009±0.06 g/cm3(Predicted)
• PKA: 14.97±0.20(Predicted)
• CAS DataBase Reference: (S)-3-methylpyrrolidin-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-methylpyrrolidin-3-ol(1312756-35-6)
• EPA Substance Registry System: (S)-3-methylpyrrolidin-3-ol(1312756-35-6)

Safety Data

• Hazardous Substances Data: 1312756-35-6(Hazardous Substances Data)

Usage

General Description

(S)-3-methylpyrrolidin-3-ol, also known as (S)-nicotinamide, is a chemical compound that belongs to the pyrrolidine group of organic compounds. It is a chiral molecule, meaning it has an asymmetric carbon atom, and can exist in two enantiomeric forms, with (S)-3-methylpyrrolidin-3-ol being the S enantiomer. (S)-3-methylpyrrolidin-3-ol is commonly used in organic synthesis and pharmaceutical research, and has been found to have potential applications in the development of new drugs and therapeutic agents. It is also a precursor for the synthesis of other important organic compounds, making it a valuable building block in the field of organic chemistry. Additionally, (S)-3-methylpyrrolidin-3-ol has been studied for its neuroprotective and anti-inflammatory properties, and may have potential therapeutic uses in the treatment of various neurodegenerative and inflammatory diseases.

Upstream product

• 96567-93-0 1-benzyl-3-methylpyrrolidin-3-ol 

Downstream Products

• 2135304-43-5 6-((3S,4S)-3,4-dihydroxypyrrolidin-1-yl)-2-((S)-3-hydroxy-3-methylpyrrolidin-1-yl)-4-(triifluoromethyl)nicotinonitrile 
• 2135304-43-5 6-[(3R,4S)-3,4-dihydroxypyrrolidin-1-yl]-2-[(3S)-3-hydroxy-3-methylpyrrolidin-1-yl]-4-(trifluoromethyl)pyridine-3-carbonitrile 
• 1620690-31-4 C₂₄H₃₁FN₄O₃ 
• 1609200-79-4 (1aR,7bS)-5-{4-fluoro-2-[(Z)-3-(3-hydroxy-3-methylpyrrolidin-1-yl)prop-1-enyl]benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid 
• 1609201-38-8 methyl (1aR,7bS)-5-(N-{4-fluoro-2-[(Z)-3-(3-hydroxy-3-methylpyrrolidin-1-yl)prop-1-enyl]benzenesulfonyl}-N-(methoxycarbonyl)amino)-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylate 
• 1453499-05-2 4-benzyloxy-1-{2-[4-(3-hydroxy-3-methyl-pyrrolidin-1-ylmethyl )-2-methyl-phenyl]-2-oxo-ethyl}-1H-pyridin-2-one 

Relevant articles and documents

Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK)

Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to further elucidate the effect of KHK inhibition on these metabolic disorders. Until now, studies on KHK inhibition with small molecules have been limited due to the lack of viable in vivo pharmacological tools. Herein we report the discovery of 12, a selective KHK inhibitor with potency and properties suitable for evaluating KHK inhibition in rat models. Key structural features interacting with KHK were discovered through fragment-based screening and subsequent optimization using structure-based drug design, and parallel medicinal chemistry led to the identification of pyridine 12.

AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment

Novel Compounds 679

The invention provides compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy, wherein R1, R2, R3